WallStreetZenWallStreetZen

NASDAQ: AMRX
Amneal Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for AMRX

Based on 4 analysts offering 12 month price targets for Amneal Pharmaceuticals Inc.
Min Forecast
$8.00+5.26%
Avg Forecast
$8.25+8.55%
Max Forecast
$9.00+18.42%

Should I buy or sell AMRX stock?

Based on 4 analysts offering ratings for Amneal Pharmaceuticals Inc.
Strong Buy
Strong Buy
4 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AMRX stock forecasts and price targets.

AMRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-06
lockedlocked$00.00+00.00%2024-05-06
lockedlocked$00.00+00.00%2024-03-21Find Out Why
lockedlocked$00.00+00.00%2024-01-29

1 of 1

Forecast return on equity

Is AMRX forecast to generate an efficient return?
Company
N/A
Industry
37.2%
Market
80.78%

Forecast return on assets

Is AMRX forecast to generate an efficient return on assets?
Company
N/A
Industry
17.66%

AMRX earnings per share forecast

What is AMRX's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$0.52
Avg 2 year Forecast
$0.53
Avg 3 year Forecast
$0.63

AMRX revenue forecast

What is AMRX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$2.6B+5.51%
Avg 2 year Forecast
$2.7B+9.75%
Avg 3 year Forecast
$2.9B+14.49%
AMRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AMRX revenue growth forecast

How is AMRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
4.58%
Industry
7.75%
Market
11.49%
AMRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AMRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AMRX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
AMRX$7.60$8.25+8.55%Strong Buy
AMPH$39.64$65.50+65.24%Strong Buy
BHC$7.55$11.00+45.70%Hold
EVO$4.78N/AN/A
AVDL$16.91$24.17+42.92%Strong Buy

Amneal Pharmaceuticals Stock Forecast FAQ

Is Amneal Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: AMRX) stock is to Strong Buy AMRX stock.

Out of 4 analysts, 4 (100%) are recommending AMRX as a Strong Buy, 0 (0%) are recommending AMRX as a Buy, 0 (0%) are recommending AMRX as a Hold, 0 (0%) are recommending AMRX as a Sell, and 0 (0%) are recommending AMRX as a Strong Sell.

If you're new to stock investing, here's how to buy Amneal Pharmaceuticals stock.

What is AMRX's earnings growth forecast for 2024-2026?

(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 20.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.86%.

Amneal Pharmaceuticals's earnings in 2024 is -$168,693,000.On average, 3 Wall Street analysts forecast AMRX's earnings for 2024 to be $160,498,714, with the lowest AMRX earnings forecast at $132,720,090, and the highest AMRX earnings forecast at $179,017,796. On average, 3 Wall Street analysts forecast AMRX's earnings for 2025 to be $163,585,228, with the lowest AMRX earnings forecast at $138,893,118, and the highest AMRX earnings forecast at $179,017,796.

In 2026, AMRX is forecast to generate $194,450,365 in earnings, with the lowest earnings forecast at $194,450,365 and the highest earnings forecast at $194,450,365.

What is AMRX's revenue growth forecast for 2024-2026?

(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 4.58% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.49%.

Amneal Pharmaceuticals's revenue in 2024 is $2,495,258,000.On average, 3 Wall Street analysts forecast AMRX's revenue for 2024 to be $812,616,100,229, with the lowest AMRX revenue forecast at $803,382,485,754, and the highest AMRX revenue forecast at $817,620,573,591. On average, 3 Wall Street analysts forecast AMRX's revenue for 2025 to be $845,255,056,970, with the lowest AMRX revenue forecast at $832,494,483,256, and the highest AMRX revenue forecast at $861,168,195,807.

In 2026, AMRX is forecast to generate $881,742,896,331 in revenue, with the lowest revenue forecast at $854,995,168,347 and the highest revenue forecast at $908,490,624,316.

What is AMRX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: AMRX) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 17.66%.

What is AMRX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year AMRX price target, the average AMRX price target is $8.25, with the highest AMRX stock price forecast at $9.00 and the lowest AMRX stock price forecast at $8.00.

On average, Wall Street analysts predict that Amneal Pharmaceuticals's share price could reach $8.25 by May 6, 2025. The average Amneal Pharmaceuticals stock price prediction forecasts a potential upside of 8.55% from the current AMRX share price of $7.60.

What is AMRX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: AMRX) Amneal Pharmaceuticals's current Earnings Per Share (EPS) is -$0.74. On average, analysts forecast that AMRX's EPS will be $0.52 for 2024, with the lowest EPS forecast at $0.43, and the highest EPS forecast at $0.58. On average, analysts forecast that AMRX's EPS will be $0.53 for 2025, with the lowest EPS forecast at $0.45, and the highest EPS forecast at $0.58. In 2026, AMRX's EPS is forecast to hit $0.63 (min: $0.63, max: $0.63).

What is AMRX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: AMRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.